Boehringer’s nerandomilast meets endpoint in Phase III study

Boehringer Ingelheim today revealed that the FIBRONEER-ILD trial of nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity (FVC) [mL] at week 52 versus placebo.

The German family-owned pharma major noted that FVC is a measure of lung function.  Initial data readouts of the FIBRONEER-trials support a generally consistent safety and tolerability profile when compared to the Phase II idiopathic pulmonary fibrosis (IPF) study, with overall adverse events comparable to those seen in the placebo group. 3